Who Owns XTLB?

XTL Biopharmaceuticals Ltd. — Institutional Ownership & 13F Holdings

$0.58

-0.01 (-1.86%)

Market Cap

$956K

Shares Outstanding

Institutional Holders

4

Total Inst. Value

$60K

% of Float Held

QoQ Holder Change

-1

Institutional data as of Q1 2025

New Positions

4

Closed Positions

0

Increased

0

Decreased

0

Institutional Ownership Trend

Top 10 Institutional Holders(Q1 2025)

#FundValueShares
1CITADEL ADVISORS LLCNew$31K25,211
2MORGAN STANLEYNew$15K13,251
3RHUMBLINE ADVISERSNew$14K10,954
4Noked Israel LtdNew$238198,888

Biggest Buyers & Sellers This Quarter

Top Buyers

FundShares AddedValue
CITADEL ADVISORS LLCNew+25K$31K
MORGAN STANLEYNew+13K$15K
RHUMBLINE ADVISERSNew+11K$14K
Noked Israel LtdNew+199K$238

Top Sellers

FundShares RemovedValue

Related Stocks

Frequently Asked Questions

How many institutional investors hold XTLB?

As of Q1 2025, 4 institutional investors report holding XTLB (XTL Biopharmaceuticals Ltd.) in their 13F filings.

Which hedge fund owns the most XTLB?

The largest institutional holder of XTLB is CITADEL ADVISORS LLC with $31K in shares.

Are institutions buying or selling XTLB?

This quarter, 4 institutions opened new positions in XTLB and 0 closed their positions.

What is 13F institutional ownership?

SEC Form 13F is a quarterly report filed by institutional investment managers with over $100M in qualifying assets. It discloses their US equity holdings, providing transparency into what the largest investors are buying and selling.

How often is institutional ownership data updated?

13F filings are due 45 days after each calendar quarter end (May 15, Aug 14, Nov 14, Feb 14). Data is updated on HedgeTrace as new filings are processed.